Intravesical BCG Administration to Patients With Invasive Bladder Cancer

• Status: Terminated
• Trial end date: 2019-04-25
• Target enrollment: 0
• Participant gender: All

Summary

Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio

Criteria

Inclusion Criteria:

1. Have suspected or known invasive (≥T1) bladder cancer

2. Be able to give informed consent

3. Be age 18 or older

4. Not be in an immunosuppressed state (e.g. HIV+, use of chronic steroids >1 month)

Exclusion Criteria:

1. Have non-invasive (2. Unable to give informed consent

3. < 18 or older

4. Is in an immunosuppressed state (e.g. HIV+, use of chronic steroids >1 month)